⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 15, 2024

Supplementary Figure S2 from Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma

Karl J. Habashy Crismita Dmello Li Chen Víctor A. Arrieta Kwang‐Soo Kim Andrew Gould Mark W. Youngblood Guillaume Bouchoux Kirsten B. Burdett Hui Zhang Michael Canney Roger Stupp Adam M. Sonabend

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 2. Human glioma cell lines exhibit variable responses to paclitaxel and carboplatin. (A) Dose-response curves showing the response to PTX (blue) and CBDCA (red) in human cell lines. (B) Bar chart showing the maximal efficacy (Emax) of PTX and CBDCA against human glioma cell lines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Habashy et al. (2024) studied this question.

synapsesocial.com/papers/68e6f2aeb6db64358766da20 https://doi.org/10.1158/1078-0432.25603404

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma2024
2Supplementary Figure S3 from Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma2024
3Supplementary Figure S3 from Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma2024
4Supplementary Figure S4 from Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma2024
5Supplementary Figure S4 from Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma2024